The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly
and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as
measured by haemoglobin at week 24 and secondly to demonstrate the non-inferiority of
efficacy between once weekly and once every two weeks dose schedules of Dynepo in patients
previously stable on EPO, as measured by Hb over Weeks 16 to 24.